SCHEMBL10102731

SCHEMBL10102731

O=C(O)CCCCCCCNC(=O)/C=C/c1ccccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
HDAC3 O15379 7/20 0.55
HDAC4 P56524 7/20 0.55
HDAC1 Q13547 7/20 0.55
HDAC7 Q8WUI4 7/20 0.55
HDAC2 Q92769 7/20 0.55
HDAC10 Q969S8 7/20 0.55
HDAC11 Q96DB2 7/20 0.55
HDAC8 Q9BY41 7/20 0.55
HDAC6 Q9UBN7 7/20 0.55
HDAC9 Q9UKV0 7/20 0.55
HDAC5 Q9UQL6 7/20 0.55
KMT2A Q03164 3/20 0.51
EGFR P00533 1/20 0.51
MEN1 O00255 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
CACNA1B Q00975 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102770 0.95 KMT2A (0.56) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL14490544 0.90 HDAC3 (0.55) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL17219109 0.89 SMN1; SMN2 (0.50) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL15854197 0.89 SMN1; SMN2 (0.50) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL14088975 0.85 POLB (0.60) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL5753211 0.85 EGFR (0.67) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL15854220 0.85 KMT2A (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL19248894 0.84 KMT2A (0.51) POLBHDAC3HDAC4HDAC1HDAC7
Hydrochloric Acid SCHEMBL17219703 0.84 KMT2A (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
Hydrochloric Acid SCHEMBL17219701 0.84 KMT2A (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220133685-A1 FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS RECEPTOR HOLDINGS, INC. (US) 2022-05-05 US disclosed
US-11246852-B2 Fast-acting plant-based medicinal compounds and nutritional supplements RECEPTOR HOLDINGS, INC. (US) 2022-02-15 US disclosed
US-20210393575-A1 N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS RECEPTOR HOLDINGS, INC. (US) 2021-12-23 US disclosed
EP-2409569-B1 Method for administering GLP-1 molecules EMISPHERE TECH INC (US) 2017-08-16 EP disclosed
EP-1478233-B1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECH INC (US) 2016-11-09 EP disclosed
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2015-07-23 US disclosed
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2015-07-23 US disclosed
US-8492330-B2 Formulation comprising GLP-1 EMISPHERE TECHNOLOGIES, INC. (US) 2013-07-23 US disclosed
US-8492330-B2 Formulation comprising GLP-1 EMISPHERE TECHNOLOGIES, INC. (US) 2013-07-23 US disclosed
EP-2409569-A2 Method for administering GLP-1 molecules Emisphere Technologies, Inc. (US) 2012-01-25 EP disclosed
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2011-07-21 US disclosed
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2011-07-21 US disclosed
US-7939494-B2 Method for administering GLP-1 molecules EMISPHERE TECHNOLOGIES, INC. (US) 2011-05-10 US disclosed
US-7939494-B2 Method for administering GLP-1 molecules EMISPHERE TECHNOLOGIES, INC. (US) 2011-05-10 US disclosed
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2009-11-19 US disclosed
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2009-11-19 US disclosed
US-7417022-B2 Compounds and compositions for delivering active agents MHR INSTITUTIONAL PARTNERS IIA LP (US) 2008-08-26 US disclosed
US-7417022-B2 Compounds and compositions for delivering active agents MHR INSTITUTIONAL PARTNERS IIA LP (US) 2008-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11246852-B2 Fast-acting plant-based medicinal compounds and nutritional supplements SLC1A5, SLC43A1, SLC27A2 POLB 1772/4885HDAC3 1689/4885HDAC4 1168/4885
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 POLB 4857/4885HDAC3 2912/4885HDAC4 3003/4885
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 POLB 4857/4885HDAC3 2912/4885HDAC4 3003/4885
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 POLB 4857/4885HDAC3 2912/4885HDAC4 3003/4885
US-20210393575-A1 N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS FAAH, CNR2, FABP2 POLB 4489/4885HDAC3 3173/4885HDAC4 3491/4885
US-20220133685-A1 FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS SLC1A5, SLC43A1, SLC27A2 POLB 1772/4885HDAC3 1689/4885HDAC4 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.